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Abstract
Background: The gene encoding fibroblast growth factor receptor 1 (FGFR1) is emerging as a therapeutic and
prognostic biomarker in various cancer types, including head and neck squamous cell carcinoma (SCC). Here, we
investigated the clinicopathologic implication of FGFR1 gene amplification and protein overexpression in hypopharyngeal
and laryngeal SCC.
Methods: Fluorescence in situ hybridization and immunohistochemistry were performed to determine FGFR1 gene
amplification and protein overexpression in 209 surgically resected cases.
Results: FGFR1 amplification observed in 8 (8/66, 12.1%; 6 hypopharynx and 2 larynx) patients and high FGFR1 expression in
21 (21/199, 10.6%) patients significantly correlated with lymph node metastasis and advanced pathological stages. FGFR1
amplification was also associated with worse disease-free survival in multivariate analysis (hazard ratio = 4.527, P= 0.032). High
FGFR1 expression was more frequently observed, consistent with the worsening of the degree of histologic differentiation.
Conclusions: FGFR1 amplification may serve as an independent prognostic factor for disease-free survival in
hypopharyngeal and laryngeal SCC. Aberrant FGFR signaling caused by FGFR1 gene amplification or protein
overexpression may play a crucial role in the malignant evolution and progression of hypopharyngeal and
laryngeal SCC, and offer novel therapeutic opportunities in patients with hypopharyngeal and laryngeal SCC
that usually lack specific therapeutic targets.
Keywords: Fibroblast growth factor receptor 1 (FGFR1), Amplification, Fluorescence in situ hybridization,
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Background
Head and neck squamous cell carcinoma (HNSCC)
arises from the squamous mucosa of the upper aerodi-
gestive tract, which comprises the nasal cavity, paranasal
sinus, oral cavity, nasopharynx, oropharynx, hypophar-
ynx, and larynx. These distinct anatomic subsites con-
tribute to the morphological, biological, and etiological
heterogeneities of HNSCC. Cigarette smoking and alco-
hol consumption are the most common risk factors, es-
pecially for hypopharyngeal and laryngeal SCC [1, 2],
while infection with high-risk human papilloma virus
(HPV) has also been recognized as a risk factor associ-
ated with oropharyngeal SCC [3]. Recent studies have
shown that HPV-positive SCC, mainly oropharyngeal
SCC, exhibits significantly favorable survival outcomes
[4–6]. However, SCCs of the hypopharynx and larynx,
the second most common respiratory tract cancer after
lung cancer, that represent HPV-negative HNSCCs are
related to little improvement in patient outcomes despite
multidisciplinary treatments because of frequent locore-
gional recurrences, distant metastases, and second pri-
mary tumors [7, 8].
The Cancer Genome Atlas (TCGA) has recently iden-
tified potentially targetable somatic genomic alterations
based on HPV infection status, smoking, and primary
tumor sites in HNSCC [9]. HPV-negative tumors are
characterized with recurrent focal amplifications in re-
ceptor tyrosine kinases and fibroblast growth factor re-
ceptor 1 (FGFR1; 10% frequency) is the second most
commonly observed gene after EGFR (15% frequency).
The gene encoding FGFR1 is located on chromosome
8p11.23 and encodes tyrosine kinase family, which plays
crucial roles in cancer development. This gene is dys-
regulated by amplification, point mutation, transloca-
tion, and overexpression in various cancers [10]. These
aberrant FGFR1 alterations, in general, lead to gain-of-
function characteristics and constitutively activate the
downstream RAS/mitogen-activated protein kinase
(MAPK), PI3K/protein kinase B (AKT), and Janus kin-
ase (JAK)/signal transducer and activator of transcrip-
tion (STAT) signaling pathways [11]. In previous
studies of HNSCC, FGFR1 amplification has been re-
ported in 3 to 17% of cases, and FGFR1 protein overex-
pression has been identified in about 11–82% of cases
[12–18]. However, they presented conflicting results for
FGFR1 as a prognostic biomarker. In addition, most of
the studies have been conducted on the whole HNSCCs
showing biological heterogeneity, and site-specific stud-
ies have been rarely performed on SCC, especially in
SCCs of hypopharynx and larynx, which represent the
prevalent subsites of HPV-negative SCC [13–19].
Therefore, more evidence is needed for the prognostic
or predictive role of FGFR1 in HNSCC of hypopharynx
and larynx.
As a predictive marker for drug response, FGFR1 has
been identified in preclinical or clinical studies of lung
SCC or breast cancer [19–21]. Recently, several nonselec-
tive or selective tyrosine kinase inhibitors suppressing
FGFR1 expression, such as lucitanib (E3810), dovitinib
(TKI258), ponatinib (AP24534), AZD4547, BGJ398, and
TAS-120, have shown promising data or are currently be-
ing investigated in preclinical models and clinical trials on
solid tumors, including HNSCC (NCT02706691,
NCT02795156) [22, 23]. However, effective targeted ther-
apies for advanced HNSCC are still limited to the anti-
EGFR monoclonal antibody, cetuximab, in HNSCC [24].
In this study, we evaluated FGFR1 gene amplification
and protein overexpression and investigated its clinico-
pathologic and prognostic implications in hypopharyn-
geal and laryngeal SCC.
Methods
Patients and tissue samples
Archived formalin-fixed, paraffin-embedded (FFPE)
specimens were obtained from patients with surgically
resected primary hypopharyngeal and laryngeal SCC.
The surgical resections, such as traditional or transoral
robotic laryngopharyngectomy, excision, and cordect-
omy, were performed at Severance Hospital, Seoul,
South Korea and National Health Insurance Service
Ilsan Hospital, Goyang, South Korea, between 2005 and
2012 for curative aim. From the consecutive cases, 209
cases were selected when tumor tissues, clinical data (in-
cluding smoking status), and survival data were available;
patients received no preoperative treatment, and no clin-
icopathological evidences of distant metastasis were re-
ported at the time of surgery. Relapsed patients were
excluded. After surgery, some patients received adjuvant
treatment, such as chemotherapy, radiotherapy, and con-
current chemoradiation therapy, based on the National
Comprehensive Cancer Network (NCCN) guidelines and
clinical judgment.
Two pathologists (S.O.Y. and E.K.K.) evaluated the
histologic features, including tumor location, size, grade,
metastasis to regional lymph nodes, lymphovascular in-
vasion, and perineural invasion, and confirmed the histo-
pathologic diagnosis. Tumors were classified according
to the eighth American Joint Committee on Cancer
(AJCC) cancer system [25] and the World Health
Organization system [2]. Clinical data were collected
and reviewed as per patients’ medical records. Smoking
status was defined as follows; “Never smokers” are those
who have smoked less than 100 cigarettes in their life-
time, “former smokers” are those who have quit smoking
for more than 12months, and “current smokers” are
those who are currently smoking or who have quit
smoking for less than 12 months [26]. Alcohol consump-
tion status was assessed as pure alcohol consumption,
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calculated as gram per day according to the average
amount, frequency, and type. “Heavy drinkers” were
those who consumed more than 30 g/day, and those
who drank less were defined as “social drinkers” [27].
The study was approved by the Institutional Review
Board of Severance Hospital (4–2015-0954) and Na-
tional Health Insurance Service Ilsan Hospital (NHIMC
2018–04-021).
Tissue microarray (TMA) construction
Sections of FFPE tissues were prepared and stained with
hematoxylin and eosin. The representative areas of tumors
were confirmed and selected to obtain a TMA under the
microscope. One to three different representative areas
per case were selected, and core tissues (3mm in diam-
eter) were obtained from the individual FFPE blocks. Con-
sidering the possibility of heterogeneity, randomly selected
35 cases were stained on whole section slides.
FGFR1 fluorescence in situ hybridization (FISH)
We conducted the FISH assay on the TMAs using com-
mercially available FGFR1 probes that hybridized to the
8p12–8p11.23 region using the fluorophore, Spectrum
Orange (red) and to the centromere region of chromo-
some 8 (CEP 8) using the fluorophore, Spectrum Green
(Abbott Molecular, Abbott Park, IL) following the man-
ufacturers’ protocol. FISH results were interpreted by
two expert evaluators (S.O.Y. and E.K.K.) without know-
ing the clinical information. Cells with sharp borders of
nuclei, no signs of over-digestion, or non-overlapping
nuclei were counted. Normal tissues including blood
vessels, fibroblasts, or adjacent normal squamous epithe-
lium served as internal positive controls. Tumor tissue
was scanned for hot spots under 40× or 63× objective
lens. Twenty contiguous tumor cell nuclei from three
hot spots or random areas resulting in a total of 60 nu-
clei were individually evaluated under the 100× objective
lens by counting red FGFR1 and green CEP8 signals.
FGFR1 gene amplification was defined as 1) an FGFR1/
CEP8 ratio of at least 2 and the average number of
FGFR1 signals per tumor cell nucleus of at least 4 or 2)
an average number of FGFR1 signals per tumor cell nu-
cleus of at least 6 [15, 28].
FGFR1 immunohistochemistry (IHC)
FGFR1 protein expression was evaluated with IHC using a
rabbit polyclonal anti-FGFR1 antibody (Clone ab10646, 1:
1500 dilution, Abcam, Cambridge, UK) on 4-μm TMA tis-
sue sections on a Ventana Bench Mark XT Autostainer
(Ventana Medical Systems, Tucson, AZ, USA). FGFR1
staining pattern (cytoplasmic, membranous, or nuclear)
and intensity (0, negative; 1, weak; 2, moderate; and 3,
strong), and the percentage of positively stained tumor
cells (0–100%) were evaluated. Staining pattern of normal
squamous epithelial cells and stromal cells adjacent to or
separated from tumors was compared to that of tumor
cells. In addition, IHC was performed for Snail (dilution 1:
200; Invitrogen, Thermo Fisher Scientific, CA, USA) and
Twist (dilution 1:200; Abcam, Cambridge, UK), which are
transcription factors related to epithelial mesenchymal
transition (EMT). IHC expression of FGFR1, Snail, and
Twist was analyzed using the semi-quantitative H-score
method, which yields a possible score range of 0–300 ob-
tained by multiplying the dominant intensity score with
the percentage of positive tumor cells.
In total, 171 samples subjected to p16 IHC (a mouse
monoclonal antibody, clone E0037, Ventana, AZ, USA)
at the time of diagnosis were reviewed. p16 expression
was scored as positive upon detection of at least 70% nu-
clear and cytoplasmic expression, with at least moderate
to strong intensity [29].
Statistical analysis
The chi-square, Fisher’s exact, independent-samples t-
tests, and bivariate correlation analysis were conducted
to compare the clinicopathologic parameters among pa-
tients with FGFR1 gene amplification and other protein
expression. Statistical significance was set at P < 0.05 for
all analyses. Patient survival rates were determined using
the Kaplan-Meier method, and differences in survival
rates were compared using the log-rank test. Disease-
free survival (DFS) was measured from the time of sur-
gery until disease progression, and was defined as cancer
recurrence, continuance of progressive disease without
complete remission, or cancer-related death. Overall sur-
vival (OS) was calculated from the date of surgery to the
date of death or last follow-up visit. Multivariate analysis
was performed with the Cox proportional hazard model
using several clinicopathologic parameters. All statistical
analyses were performed with IBM SPSS 22 software for
Windows (IBM Corp, Somers, New York).
Results
Demographic characteristics of patients with
hypopharyngeal and laryngeal SCC
The clinical and pathological characteristics of 209 pa-
tients are summarized in Table 1. A total of 195 (93.3%)
patients were males and 14 (6.7%) were females, with a
median age of 64 years (range 30–88 years). The cohort
comprised 54 patients with (25.8%) hypopharyngeal SCC
and 155 patients with (74.2%) laryngeal SCC. The major-
ity of patients (n = 186, 89%) were current or former
smokers, with a median smoking dosage of 30.0 pack-
years (range 0–100). Furthermore, the majority of pa-
tients (n = 149, 87.1%) were heavy drinkers. Histological
analysis revealed that most SCCs (n = 187, 89.5%) were
well to moderately differentiated and revealed p16 IHC
negativity (n = 149, 87.1%), as evident from 171 cases
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with available p16 IHC data. Advanced pT classification
(pT3 and pT4a; n = 80, 38.3%) and advanced pN classifi-
cation, especially pN3b (n = 52, 24.9%), were not uncom-
mon. TNM stages were as follows: stage I in 28.7%
cases, stage II in 13.9% cases, stage III in 15.3% cases,
stage IVA in 17.2% cases, and stage IVB in 24.9% cases.
Adjuvant treatment (concurrent chemoradiation therapy
and radiation therapy) was provided to 120 (57.4%) pa-
tients. During the observation period with a median
follow-up time of 38.8 months, 21.5% (n = 45) patients
experienced recurrence. The mean DFS and OS rates for
all patients were 82.3 months (range, 2–105 months) and
76.4 months (2–105 months), respectively. The 5-year
DFS and OS rates were 74.1 and 67.6%, respectively.
FGFR1 amplification status in hypopharyngeal and
laryngeal SCC
The FISH test was finally available for 66 cases, exclud-
ing cases with decalcified tissue, insufficient amounts of
tumor cells, or poor signals on FISH tests. Of these, 8







Median (range) 64.0 (30–88) pT1 71 (34.0)
< 65 114 (54.5) pT2 58 (27.8)
≥ 65 95 (45.5) pT3 52 (24.9)
Gender pT4a 28 (13.4)
Female 14 (6.7) pN-classification
Male 195 (93.3) pN0 118 (56.5)
Primary sites pN1 13 (6.2)
Hypopharynx 54 (25.8) pN2 26 (12.5)
Larynx 155 (74.2) pN3 52 (24.9)
Smoking Pathological stage
Never smoker 23 (11.0) Stage I 60 (28.7)
Former smoker 54 (25.8) Stage II 29 (13.9)
Current smoker 132 (63.2) Stage III 32 (15.3)
Alcohol Stage IVA 36 (17.2)
Non- or social- drinker 45 (20.1) Stage IVB 52 (24.9)
Heavy drinker 167 (79.9) Adjuvant treatment
Histologic differentiation No 89 (42.6)
Well differentiated 64 (30.6) Yes 120 (57.4)
Moderately differentiated 123 (58.9) Chemotherapy (C) 0 (0.0)
Poorly differentiated 22 (10.5) Radiation therapy (R) 71 (34.0)
Lymphovascular invasion C + R 49 (23.4)
Absent 163 (78.0) Recurrence
Present 46 (22.0) No 164 (78.5)
Perineural invasion Yes 45 (21.5)
Absent 178 (85.2) Local recurrence only 23 (51.1)
Present 31 (14.8) Distant recurrence 22 (48.9)
Positive resection margin Disease-free survival
Absent 155 (74.2) Mean (range; months) 82.3 (2–105)
Present 54 (25.8) Overall survival time
p16 status (n = 171) Mean (range; months) 76.4 (2–105)
Negative 149 (87.1)
Positive 22 (12.9)
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Table 2 The status of FGFR1 gene amplification and protein overexpression in patients with hypopharyngeal and laryngeal
squamous cell carcinoma
Characteristics FGFR1 amplification, n = 66 P
value
FGFR1 high expression, n = 199 P value
Present, n (%) Absent, n (%) Present, n (%) Absent, n (%)
Total 8 (12.1) 58 (87.9) 21 (10.6) 178 (89.4)
Primary sites 0.015 0.307
Hypopharynx 6 (75.0) 36 (62.1) 6 (28.6) 47 (26.4)
Larynx 2 (25.0) 22 (37.9) 15 (71.4) 131 (73.6)
Gender 0.771 0.145
Female 0 (0.0) 2 (3.4) 3 (14.3) 10 (5.6)
Male 8 (100.0) 56 (96.6) 18 (85.7) 168 (94.4)
Age (years) 0.452 0.820
Median (range) 68.0 (55–73) 63.0 (42–88) 63.0 (45–78) 64.0 (30–88)
< 65 3 (37.5) 33 (56.9) 12 (57.1) 95 (53.4)
≥ 65 5 (62.5) 25 (43.1) 9 (42.9) 83 (46.6)
Smoking 0.405 0.302
Never smoker 2 (25.0) 7 (12.1) 3 (14.3) 19 (10.7)
Former smoker 1 (12.5) 15 (25.9) 6 (28.6) 45 (25.3)
Current smoker 5 (62.5) 36 (62.1) 12 (57.1) 114 (64.0)
Alcohol 0.196 0.778
Non- or social- drinker 0 (0.0) 13 (22.4) 5 (23.8) 37 (20.8)
Heavy drinker 8 (100.0) 45 (77.6) 16 (76.2) 141 (79.2)
p16 status 0.551 0.697
Negative 7 (87.5) 47 (81.0) 14 (82.4) 131 (88.5)
Positive 1 (12.5) 11 (19.0) 3 (17.6) 17 (11.5)
Unknown –
Histologic differentiation 0.355 < 0.001
Well differentiated 2 (25.0) 15 (25.9) 1 (4.8) 58 (32.6)
Moderately differentiated 4 (50.0) 37 (63.8) 11 (52.4) 108 (60.7)
Poorly differentiated 2 (25.0) 6 (10.3) 9 (42.9) 12 (6.7)
Lymphovascular invasion 0.031 0.096
Absent 4 (50.0) 50 (86.2) 13 (61.9) 141 (79.2)
Present 4 (50.0) 8 (13.8) 8 (38.1) 37 (20.8)
Perineural invasion 0.614 0.335
Absent 7 (87.5) 52 (89.7) 16 (76.2) 152 (85.4)
Present 1 (12.5) 6 (10.3) 5 (23.8) 26 (14.6)
Positive resection margin 0.537 0.494
Absent 4 (50.0) 32 (55.2) 16 (76.2) 130 (73.0)
Present 4 (50.0) 26 (44.8) 5 (23.8) 48 (27.0)
Pathological T-classification 0.365 0.238
pT1 3 (37.5) 29 (50.0) 4 (19.0) 59 (33.1)
pT2 4 (50.0) 18 (31.0) 9 (42.9) 49 (27.5)
pT3 0 (0.0) 10 (17.2) 4 (19.0) 48 (27.0)
pT4a 1 (9.1) 1 (1.7) 4 (19.0) 22 (12.4)
Pathological N-classification 0.012 0.003
pN0 3 (27.3) 32 (58.2) 6 (28.6) 105 (59.0)
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Table 2 The status of FGFR1 gene amplification and protein overexpression in patients with hypopharyngeal and laryngeal
squamous cell carcinoma (Continued)
Characteristics FGFR1 amplification, n = 66 P
value
FGFR1 high expression, n = 199 P value
Present, n (%) Absent, n (%) Present, n (%) Absent, n (%)
pN1 0 (0.0) 4 (7.3) 1 (4.8) 12 (6.7)
pN2 1 (9.1) 7 (12.7) 4 (19.0) 22 (12.4)
pN3 7 (63.6) 12 (21.8) 10 (47.6) 39 (21.9)
Pathological stage 0.047 0.001
Stage I 2 (25.0) 24 (41.4) 1 (4.8) 53 (29.8)
Stage II 0 (0.0) 5 (8.6) 3 (14.3) 26 (14.6)
Stage III 0 (0.0) 7 (12.1) 2 (9.5) 30 (16.9)
Stage IVA 1 (12.5) 8 (13.8) 5 (23.8) 30 (16.9)
Stage IVB 5 (62.5) 14 (24.1) 10 (47.6) 39 (21.9)
Recurrence 0.042 0.263
No 4 (50.0) 49 (84.5) 14 (66.7) 141 (79.2)
Yes 4 (50.0) 9 (15.5) 7 (33.3) 37 (20.8)
Local recurrence only 2 (50.0) 5 (55.6) 2 (28.6) 20 (54.1)
Distant recurrence 2 (50.0) 4 (44.4) 5 (71.4) 17 (45.9)
Fig. 1 FGFR1 FISH analysis and FGFR1 protein expression in hypopharyngeal and laryngeal squamous cell carcinoma (SCC). (a) Amplified FGFR1
expression is shown as red signals (yellow arrows) and CEP8 signal (white arrows) is shown as green in nuclei. Increased red signals (in number
3~6) compared to green signal (in number 1~2) could define amplification of FGFR1 gene. Scale bar represents 10 μm. (original magnification,
1000×). Representative FGFR1 immunohistochemical staining (original magnification, 200×) showing negative (b), low expression (c), and high
expression (d), and the corresponding hematoxylin and eosin-stained cases (inset; original magnification 400×) showing well differentiated SCC
(b), moderately differentiated SCC (c), and poorly differentiated SCC (d)
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(12.1%) patients displayed FGFR1 amplification (Table 2
and Fig. 1a). The mean FGFR1 copy number per nucleus
and the mean FGFR1/CEP8 ratio in all patients were
2.37 (range, 1.85 to 6.75 copies per nucleus) and 1.00
(range, 0.42 to 2.54), respectively, in 66 tested cases. The
mean FGFR1 copy number was 5.37 (range, 4.01 to 6.75)
in the amplification group and 2.48 (range 1.85 to 4.86),
in the non-amplification group. The mean FGFR1/CEP8
ratio was 2.23 (range 1.59 to 2.54) and 0.96 (range, 0.42
to 1.59) in the amplification and non-amplification
group, respectively (Supplementary Fig. 1).
The association of FGFR1 amplification with clinical
and pathological factors is summarized in Table 2. FGFR1
amplification was more frequent in hypopharyngeal SCC
than in laryngeal SCC (6/42, 14.3% versus 2/24, 8.3%; P =
0.015) and showed a significant correlation with the pres-
ence of lymphovascular invasion (P = 0.031), more ad-
vanced pathological N-classification (P = 0.020), more
advanced TNM tumor stage (P = 0.047), and more fre-
quent recurrence rate (P = 0.042) than cases with no
FGFR1 amplification. Other factors were not significant
according to FGFR1 amplification status. For the 8 cases
with FGFR1 amplified squamous cell carcinoma, the clini-
copathologic characteristics as well as detailed status
FGFR1 gene and FGFR1 protein are summarized in Sup-
plementary Table S1.
FGFR1 protein expression in hypopharyngeal and
laryngeal SCC
FGFR1 IHC was evaluable in 199 cases. FGFR1 staining ex-
hibited cytoplasmic patterns with occasional weak nuclear
patterns and was uniform in most tumor areas. The normal
squamous epithelial cells and stromal cells adjacent to or
separated from tumors were stained with an intensity from 0
to 2, and none showed strong staining with an intensity score
of 3. We found cases with predominantly strong FGFR1
staining intensity (score 3) in tumor cells, wherein positive
staining was observed in more than 80% tumor cells;
therefore, the H-score of these cases was calculated to be
more than 240 (Fig. 2a). Considering the expression pattern
of FGFR1, we defined the cutoff value for high FGFR1 ex-
pression as a strong intensity and/or H-score of more than
240. The H-score of FGFR1 was only weakly correlated in
stromal cells and tumor cells (r = 0.256, P < 0.001).
On the basis of the criteria of our series, 21 (10.6%)
patients showed high FGFR1 expression. The association
between FGFR1 overexpression and clinical and patho-
logical factors is summarized in Table 2. High FGFR1
expression was more frequently detected in poorly dif-
ferentiated histology (P < 0.001; Table 2 and Fig. 1b-d),
while well differentiated SCC showed no or low FGFR1
expression (Fig. 2b). In comparison with no or low
FGFR1 expression, high FGFR1 expression was associ-
ated with more advanced pathological N-classification
(P = 0.003) and TNM stage (P = 0.001). Other factors
were not significant according to FGFR1 expression sta-
tus (Table 2). Consistent with FGFR1 gene expression,
high FGFR1 protein expression showed a marginal ten-
dency to be related with gene amplification, although no
statistical significance was observed (Fig. 2c; P = 0.059).
Alteration of FGFR1 and epithelial mesenchymal
transition (EMT)
Snail and Twist IHC were evaluable in 67 cases. When
comparing FGFR1 amplified SCC with non-amplified
SCC, there were no statistically significant differences in
Snail and Twist expression (P = 0.344 and P = 0.637, re-
spectively; Supplementary Figure S2 and S3). The expres-
sion level of FGFR1 protein also did not correlate with the
expression levels of Snail and Twist (P = 0.904 and P =
0.402, respectively; Supplementary Figure S2 and S3).
Survival outcomes according to FGFR1 gene amplification
and protein expression
In the Kaplan-Meir analysis, patients with FGFR1 ampli-
fication were more associated with inferior DFS rate
Fig. 2 FGFR1 immunohistochemistry in hypopharyngeal and laryngeal squamous cell carcinoma. (a) FGFR1-positive tumor cells with strong intensity
were observed in more than 80% tumor area. (b) High FGFR1 expression was more frequently found in poorly differentiated histology. (c) High FGFR1
protein expression showed a marginal tendency to be related to gene amplification
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than those with no amplification (P = 0.010, Fig. 3a);
however, such significant association was not observed
for OS rate (P = 0.240, Fig. 3b). The status of FGFR1
protein expression showed no significant association
with DFS and OS (P = 0.226 and P = 0.341, respectively;
Fig. 3c and d).
In the univariate Cox proportional hazard analysis for
DFS (Table 3), poorly differentiated histology (hazard ra-
tio [HR] 3.803, P = 0.006), perineural invasion (HR 2.046,
P = 0.039), pN-classification (N2; HR 5.415; P < 0.001,
N3; HR 2.816; P = 0.005), pathologic stage (IV; HR 3.124;
P = 0.007), and FGFR1 amplification (HR 4.204, P =
0.017) were significantly related to worse DFS. Of these,
FGFR1 amplification was determined as an independent
factor for poor DFS in multivariate analysis (HR 3.666,
P = 0.049).
In the univariate Cox proportional hazard analysis for
OS (Table 4), older age (≥ 65 years, HR 2.102, P = 0.009),
primary site (hypopharynx, HR 1.812, P = 0.042), histo-
logic differentiation (moderate; HR 2.885; P = 0.007,
poor; HR 3.180, P = 0.026), lymphovascular invasion (HR
1.842, P = 0.040), perineural invasion (HR 2.608, P =
0.002), positive resection margin (HR 2.236, P = 0.006),
T-classification (T3; HR 1.715; P = 0.032, T4a; HR 2.224;
P = 0.011), pN-classification (N2; HR 2.982; P = 0.005,
N3; HR 3.003; P = 0.001), and advanced pathologic stage
(III; HR 3.890; P = 0.011, IV; HR 4.102; P = 0.004) were
significantly related to inferior OS rates. Older age (≥ 65
years, HR 1.835, P = 0.035), positive resection margin
(HR 2.712, P = 0.002), and advanced pathologic stage
(III; HR 3.018; P = 0.048, IV; HR 2.967; P = 0.046) were
identified as the independent factors for poor OS in
multivariate analysis.
Discussion
In the present study, we investigated the clinicopatho-
logic and prognostic implications of FGFR1 gene ampli-
fication and protein overexpression in hypopharyngeal
and laryngeal SCC. We analyzed a large number of cases
that underwent standard management of curative sur-
gery and appropriate adjuvant therapy in two different
institutes.
In our series, hypopharyngeal and laryngeal SCCs were
generally detected in late adulthood, and frequently re-
lated to smoking and alcohol consumption and p16 IHC
negativity. Furthermore, advanced tumor stages, espe-
cially advanced pathologic lymph node stages, were not
uncommon, and the 5-year DFS and OS rates were 74.1
Fig. 3 Kaplan-Meier survival curves for FGFR1 gene amplification (a and b) and protein overexpression (c and d) in hypopharyngeal and laryngeal
squamous cell carcinoma. FGFR1 amplification was significantly associated with disease-free survival (a) but not overall survival (b). FGFR1 protein
overexpression was not related to disease-free survival (c) or overall survival (d)
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and 67.6%, respectively, indicating that a proportion of
patients with this disease exhibited unfavorable out-
comes. These demographic features were generally simi-
lar to those previously reported and our series may be
used as a surrogate of the population-based data [30,
31]. Hypopharyngeal SCCs showed more lymph node
metastasis compared to laryngeal SCC in our study and
they were expected to have a worse prognosis than
Table 3 Cox proportional hazards regression model for disease-free survival in hypopharyngeal and laryngeal squamous cell
carcinoma
Variables Univariate Multivariate
P value HR (95% CI) P value HR (95% CI)
≥ 65 years 0.485 1.232 (0.686–2.211)
Male 0.961 1.030 (0.319–3.324)
Primary sites
Larynx 1 (reference)
Hypopharynx 0.385 1.331 (0.698–2.536)
Smoking
Never smoker 1 (reference)
Smoker 0.368 0.690 (0.308–1.546)
Alcohol
Non- or social- drinker 1 (reference)
Heavy drinker 0.196 1.763 (0.746–4.164)
Differentiation
Well 1 (reference) 1 (reference)
Moderate 0.057 2.148 (0.979–4.715) 0.687 1.340 (0.323–5.561)
Poor 0.006 3.803 (1.466–9.864) 0.883 1.154 (0.170–7.839)
Lymphovascular invasion 0.120 1.669 (0.875–3.180)
Perineural invasion 0.039 2.046 (1.035–4.040) 0.613 0.567 (0.063–5.119)
Positive resection margin 0.091 1.710 (0.919–3.185)
pT-classification
pT1 1 (reference)
pT2 0.906 1.051 (0.463–2.384)
pT3 0.178 1.715 (0.782–3.759)
pT4a 0.070 2.224 (0.936–5.282)
pN-classification
pN0 1 (reference)
pN1 0.062 2.881 (0.948–8.757)
pN2 < 0.001 5.415 (2.492–11.769)
pN3 0.005 2.816 (1.359–5.837)
Pathological stage
Stage I 1 (reference) 1 (reference)
Stage II 0.686 0.756 (0.195–2.929) 0.904 1.147 (0.124–10.594)
Stage III 0.168 2.089 (0.732–5.960) 0.982 < 0.001
Stage IV 0.007 3.124 (1.364–7.153) 0.234 2.511 (0.551–11.438)
Adjuvant treatment 0.396 1.303 (0.707–2.400)
p16 positivity 0.791 1.073 (0.637–1.806)
FGFR1 amplification 0.017 4.204 (1.290–13.698) 0.049 3.666 (1.006–13.361)
FGFR1 high expression 0.235 1.633 (0.727–3.664)
aAbbreviations: CI Confidence interval, HR Hazard ratio
bVariables of the pT and pN classification were not included in the multivariate analysis, because they were included in the pathologic stage
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laryngeal SCC. However, in Kaplan-Meier analysis and
multivariate Cox regression model, the difference be-
tween OS and DFS according to larynx and hypopharynx
was not statistically significant. Therefore, we think
combining these two groups would not cause serious
selection bias, but the concept of non-HPV related SCC
can be approached.
FGFR1 gene amplification was observed in about 12%
tested hypopharyngeal and laryngeal SCC cases that was
slightly more frequent in hypopharyngeal SCC (14.3%)
Table 4 Cox proportional hazards regression model for overall survival in hypopharyngeal and laryngeal squamous cell carcinoma
Variables Univariate Multivariate
P value HR (95% CI) P value HR (95% CI)
≥ 65 years 0.009 2.102 (1.207–3.663) 0.035 1.835 (1.042–3.231)
Male 0.503 1.493 (0.463–4.816)
Primary sites
Larynx 1 (reference) 1 (reference)
Hypopharynx 0.042 1.812 (1.022–3.213) 0.702 1.142 (0.580–2.248)
Smoking
Never smoker 1 (reference)
Smoker 0.621 1.263 (0.500–3.190)
Alcohol
Non- or social- drinker 1 (reference)
Heavy drinker 0.160 1.772 (0.798–3.937)
Differentiation
Well 1 (reference) 1 (reference)
Moderate 0.007 2.885 (1.343–6.199) 0.033 2.422 (1.076–5.452)
Poor 0.026 3.180 (1.147–8.819) 0.422 1.398 (0.532–4.513)
Lymphovascular invasion 0.040 1.842 (1.029–3.296) 0.569 0.819 (0.411–1.632)
Perineural invasion 0.002 2.608 (1.411–4.821) 0.098 1.825 (0.896–3.720)
Positive resection margin 0.006 2.236 (1.265–3.951) 0.002 2.712 (1.425–5.161)
pT-classification
pT1 1 (reference)
pT2 0.358 1.464 (0.649–3.301)
pT3 0.032 1.715 (1.076–5.171)
pT4a 0.011 2.224 (1.286–6.928)
pN-classification
pN0 1 (reference)
pN1 0.085 2.385 (0.888–6.409)
pN2 0.005 2.982 (1.382–6.431)
pN3 0.001 3.003 (1.578–5.714)
Pathological stage
Stage I 1 (reference) 1 (reference)
Stage II 0.482 1.561 (0.451–5.402) 0.457 1.625 (0.452–5.847)
Stage III 0.011 3.890 (1.361–11.117) 0.048 3.018 (1.010–9.018)
Stage IV 0.004 4.102 (1.591–10.581) 0.046 2.967 (1.018–8.647)
Adjuvant treatment 0.615 1.154 (0.661–2.013)
p16 positivity 0.127 0.331 (0.080–1.368)
FGFR1 amplification 0.252 2.128 (0.585–7.738)
FGFR1 high expression 0.319 1.504 (0.674–3.354)
aAbbreviations: CI Confidence interval, HR Hazard ratio
bVariables of the pT and pN classification were not included in the multivariate analysis, because they were included in the pathologic stage
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than in laryngeal SCC (8.3%). FGFR1 amplification has
been suggested as an oncogenic driver mutation in
tobacco-associated cancers of the aerodigestive tract [16,
32–34]. Previous studies on FGFR1 in HNSCC have
shown that FGFR1 amplification is more common in the
SCC of hypopharynx and larynx than in that of orophar-
ynx or oral cavity [14, 16]. In addition, FGFR1 amplifica-
tion has no relationship with HPV infection [13]. All
these findings are suggestive of the biological role of
FGFR1 amplification in the tumorigenesis of these to-
bacco or alcohol-related cancers, hypopharyngeal and la-
ryngeal SCCs, and may predict the role of targeted
therapy for these tumors [30, 31].
Considering the clinical implications of FGFR1 amplifi-
cation, we observed significant association with poor prog-
nostic factors, specifically, lymphovascular invasion and
advanced stages of lymph node metastasis. This observa-
tion may be related to our findings that cases with FGFR1
amplification were closely associated with advanced TNM
tumor stages and poorer DFS. In particular, FGFR1 ampli-
fication was determined as an independent factor for dis-
ease progression and thus, may be involved in the
invasion, metastasis, and drug resistance of tumor cells
during the development of treatment-resistant, aggressive,
advanced hypopharyngeal and laryngeal SCCs. Several
studies have also shown that FGFR1 amplification plays a
role in the invasion, metastasis, and drug resistance of
various tumors [32, 35]. A recent study performed gen-
omic profiling of HNSCC using targeted next-generation
sequencing and identified FGFR1 amplification as an inde-
pendent prognostic factor for OS [14], while it has been
failed to impact on prognosis in other studies [15, 16, 36].
In our study, we failed to detect any association between
FGFR1 amplification and OS. Cases positive for FGFR1
amplification were relatively fewer in number in previous
and present studies; therefore, its prognostic role warrants
validation in future studies, including meta-analysis.
In our series, high FGFR1 expression was observed in
about 11% of tested cases with hypopharynx and larynx
SCCs. Similar to FGFR1 amplification, FGFR1 protein
overexpression was associated with lymph node metas-
tasis and advanced TNM tumor stages. Considering the
marginal association between high FGFR1 expression
and FGFR1 amplification, gene amplification and the
subsequent protein overexpression may be one of the
related mechanisms underlying the invasion and metas-
tasis of hypopharyngeal and laryngeal SCCs. However,
FGFR1 protein overexpression showed no effect on sur-
vival outcomes. Previous studies have shown a
disagreement with prognostic values of FGFR1 over-
expression in HNSCC, probably owing to the use of
different FGFR1 overexpression criteria, anti-FGFR1
antibodies, and cohorts with different anatomical lo-
cations [13, 17, 37].
FGFR1 demonstrated strong and diffused expression
in poorly differentiated SCC, while normal, dysplastic
squamous epithelium, or well differentiated SCC exhib-
ited weak to moderate expression patterns. In a recent
study on oral tongue SCC, FGFR1 expression was stron-
ger in high-grade dysplasia than in low-grade dysplasia
as well as in the nucleus of poorly differentiated SCC
cells [37]. However, we failed to report any increase in
nuclear staining in poorly differentiated SCC. These re-
sults suggest that FGFR1 may be one of the important
factors in the carcinogenesis and progression of HPV-
negative, smoking- and alcohol-related SCC represented
by hypopharyngeal and laryngeal SCC.
Regarding the biologic implications of FGFR1 gene
amplification or protein overexpression in hypopharyngeal
and laryngeal SCC, we investigated a correlation of FGFR1
alteration with twist and snail, the well-known EMT
markers, on the basis of previous studies showing that
EMT is induced in tumors by abnormal activation of the
FGFR signaling pathway in several types of cancers includ-
ing HNSCC [38–41]. However, we did not observe that
amplification or high protein expression of FGFR1 is re-
lated to overexpression of these two EMT-related pro-
teins. Therefore, further studies are needed to determine
whether changes in FGFR1 affect EMT acquisition in
hypopharyngeal and laryngeal SCC. In addition, further
in-depth studies should be followed for the underlying
mechanisms of aberrant FGFR1 alterations in the tumori-
genesis of hypopharyngeal and laryngeal SCC in the aspect
of the known downstream signals of RAS/MAPK, PI3K/
AKT, and JAK/STAT signaling pathways [11].
FGFR1 gene amplification and protein or mRNA ex-
pression have demonstrated correlation in some previ-
ous studies [23, 28]. However, we could not find any
strong correlation between FGFR1 gene amplification
and protein overexpression. This discrepancy may be as-
sociated with the differences in the cutoff level of ampli-
fication and protein or mRNA expression among various
studies. Furthermore, FGFR1 amplification may not
always cause protein overexpression alone, and may be
affected by other closely related receptor tyrosine kinases
(RTK). In lung SCC, some researchers suggested the
mechanism of discrepancy between protein expression
and gene amplification of FGFR1 due to crosstalk
between FGFR1 and co-activated RTKs in FGFR1-
amplified lung cancers with low FGFR1 protein expres-
sion [42, 43].
Conclusions
In summary, we report that FGFR1 gene amplification
and protein overexpression occur in hypopharyngeal and
laryngeal SCC with an incidence of 12.1 and 10.6%, re-
spectively. High FGFR1 expression was more frequent
with the worsening of histologic differentiation. In
Kim et al. BMC Cancer          (2020) 20:348 Page 11 of 13
addition, FGFR1 amplification appeared as an independ-
ent prognostic factor for DFS and may serve as a prog-
nostic biomarker. These results suggest that the altered
FGFR1 pathways play an important role in the malignant
evolution and progression of hypopharyngeal and laryn-
geal SCC. Several emerging FGFR1-targeted therapies
may shed light on treatment of patients with hypophar-
yngeal and laryngeal SCC that usually lack specific thera-
peutic targets.
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